New targets for the antitumor activity of gambogic acid in hematologic malignancies

Acta Pharmacologica Sinica

Volumn 34, Issue 2, 2013, Pages 191-198

  Yang, Li Jing ^a   Chen, Yan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

death inducer obliterator; gambogic acid; hematological malignancies; HERG channel; nucleophosmin; nucleoporin; reactive oxygen species; steroid receptor coactivator 3

Indexed keywords

GAMBOGIC ACID; NUCLEOPHOSMIN; NUCLEOPORIN; POTASSIUM CHANNEL HERG; REACTIVE OXYGEN METABOLITE; STEROID RECEPTOR COACTIVATOR 3;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL PROLIFERATION; DOWN REGULATION; DRUG MECHANISM; HEMATOLOGIC MALIGNANCY; HUMAN; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DNA-BINDING PROTEINS; ETHER-A-GO-GO POTASSIUM CHANNELS; GARCINIA; HEMATOLOGIC NEOPLASMS; HUMANS; NUCLEAR PORE COMPLEX PROTEINS; NUCLEAR PROTEINS; NUCLEAR RECEPTOR COACTIVATOR 3; REACTIVE OXYGEN SPECIES; XANTHONES;

EID: 84873561991     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.163     Document Type: Review

References (79)

1. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005; 11: 3155-62.
2. Fulda S. Betulinic acid: a natural product with anticancer activity. Mol Nutr Food Res 2009; 53: 140-6.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
4. Prasad S, Pandey MK, Yadav VR, Aggarwal BB. Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer Prev Res (Phila) 2011; 4: 1084-94.
5. Nie F, Zhang X, Qi Q, Yang L, Yang Y, Liu W, et al. Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology 2009; 260: 60-7.
6. Wu ZQ, Guo QL, You QD, Zhao L, Gu HY. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 2004; 27: 1769-74.
7. Guo QL, You QD, Wu ZQ, Yuan ST, Zhao L. General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol Sin 2004; 25: 769-74.
8. Xie H, Qin YX, Zhou YL, Tong LJ, Lin LP, Geng MY, et al. GA3, a new gambogic acid derivative, exhibits potent antitumor activities in vitro via apoptosis-involved mechanisms. Acta Pharmacol Sin 2009; 30: 346-54.
9. Yang Y, Yang L, You QD, Nie FF, Gu HY, Zhao L, et al. Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett 2007; 256: 259-66.
10. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004; 4: 106-17.
11. Jamali T, Jamali Y, Mehrbod M, Mofrad MR. Nuclear pore complex: biochemistry and biophysics of nucleocytoplasmic transport in health and disease. Int Rev Cell Mol Biol 2011; 287: 233-86.
12. Xu S, Powers MA. Nuclear pore proteins and cancer. Semin Cell Dev Biol 2009; 20: 620-30.
13. Hashizume C, Nakano H, Yoshida K, Wong RW. Characterization of the role of the tumor marker Nup88 in mitosis. Mol Cancer 2010; 9: 119.
14. Fornerod M, van Deursen J, van Baal S, Reynolds A, Davis D, Murti KG, et al. The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J 1997; 16: 807-16.
15. Roth P, Xylourgidis N, Sabri N, Uv A, Fornerod M, Samakovlis C. The Drosophila nucleoporin DNup88 localizes DNup214 and CRM1 on the nuclear envelope and attenuates NES-mediated nuclear export. J Cell Biol 2003; 163: 701-6.
16. Xylourgidis N, Roth P, Sabri N, Tsarouhas V, Samakovlis C. The nucleoporin Nup214 sequesters CRM1 at the nuclear rim and modulates NFkappaB activation in Drosophila. J Cell Sci 2006; 119: 4409-19.
17. Schneider J, Moragues D, Martinez N, Romero H, Jimenez E, Ponton J. Cross-reactivity between Candida albicans and human ovarian carcinoma as revealed by monoclonal antibodies PA10F and C6. Br J Cancer 1998; 77: 1015-20.
18. Gould VE, Orucevic A, Zentgraf H, Gattuso P, Martinez N, Alonso A. Nup88 (karyoporin) in human malignant neoplasms and dysplasias: correlations of immunostaining of tissue sections, cytologic smears, and immunoblot analysis. Hum Pathol 2002; 33: 536-44.
19. Agudo D, Gomez-Esquer F, Martinez-Arribas F, Nunez-Villar MJ, Pollan M, Schneider J. Nup88 mRNA overexpression is associated with high aggressiveness of breast cancer. Int J Cancer 2004; 109: 717-20.
20. Takahashi N, van Kilsdonk JW, Ostendorf B, Smeets R, Bruggeman SW, Alonso A, et al. Tumor marker nucleoporin 88 kDa regulates nucleocytoplasmic transport of NF-kappaB. Biochem Biophys Res Commun 2008; 374: 424-30.
21. Shu W, Chen Y, He J, Cui G. Effects of gambogic acid on the regulation of nucleoporin Nup88 in U937 cells. J Huazhong Univ Sci Technolog Med Sci 2007; 27: 388-92.
22. Shu WX, Chen Y, He J. Effects of gambogic acid on the regulation of nucleoporin Nup88 in HL-60 cells. Zhonghua Zhong Liu Za Zhi 2008; 30: 484-9.
23. Shu W, Chen Y, Li R, Wu Q, Cui G, Ke W, et al. Involvement of regulations of nucleophosmin and nucleoporins in gambogic acid-induced apoptosis in Jurkat cells. Basic Clin Pharmacol Toxicol 2008; 103: 530-7.
24. Yun JP, Chew EC, Liew CT, Chan JY, Jin ML, Ding MX, et al. Nucleophosmin/B23 is a proliferate shuttle protein associated with nuclear matrix. J Cell Biochem 2003; 90: 1140-8.
25. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493-505.
26. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-66.
27. Hsu CY, Yung BY. Involvement of nucleophosmin/B23 in TPA-induced megakaryocytic differentiation of K562 cells. Br J Cancer 2003; 89: 1320-6.
28. Hsu CY, Yung BY. Over-expression of nucleophosmin/B23 decreases the susceptibility of human leukemia HL-60 cells to retinoic acidinduced differentiation and apoptosis. Int J Cancer 2000; 88: 392-400.
29. Suen CS, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR, Frail DE. A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem 1998; 273: 27645-53.
30. Gojis O, Rudraraju B, Alifrangis C, Krell J, Libalova P, Palmieri C. The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease. Eur J Surg Oncol 2010; 36: 224-9.
31. Ma G, Ren Y, Wang K, He J. SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int J Biol Sci 2011; 7: 664-72.
32. Amazit L, Pasini L, Szafran AT, Berno V, Wu RC, Mielke M, et al. Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation. Mol Cell Biol 2007; 27: 6913-32.
33. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277: 965-8.
34. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000; 6: 1833-9.
35. Glaeser M, Floetotto T, Hanstein B, Beckmann MW, Niederacher D. Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm Metab Res 2001; 33: 121-6.
36. He LR, Liu MZ, Li BK, Rao HL, Deng HX, Guan XY, et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci 2009; 100: 1591-6.
37. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H. Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? Int J Colorectal Dis 2009; 24: 613-22.
38. Xu Y, Chen Q, Li W, Su X, Chen T, Liu Y, et al. Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness. Oncogene 2010; 29: 3386-97.
39. Henke RT, Haddad BR, Kim SE, Rone JD, Mani A, Jessup JM, et al. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res 2004; 10: 6134-42.
40. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004; 6: 263-74.
41. Colo GP, Rosato RR, Grant S, Costas MA. RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett 2007; 581: 5075-81.
42. Esteyries S, Perot C, Adelaide J, Imbert M, Lagarde A, Pautas C, et al. NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia 2008; 22: 663-5.
43. Colo GP, Rubio MF, Nojek IM, Werbajh SE, Echeverria PC, Alvarado CV, et al. The p160 nuclear receptor co-activator RAC3 exerts an antiapoptotic role through a cytoplasmatic action. Oncogene 2008; 27: 2430-44.
44. Li R, Chen Y, Zeng LL, Shu WX, Zhao F, Wen L, et al. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells. Toxicology 2009; 262: 98-105.
45. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455: 1205-9.
46. Tazzari PL, Cappellini A, Grafone T, Mantovani I, Ricci F, Billi AM, et al. Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry. Br J Haematol 2004; 126: 675-81.
47. Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res 2006; 66: 11039-46.
48. Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, et al. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004; 23: 5781-91.
49. Garcia-Domingo D, Leonardo E, Grandien A, Martinez P, Albar JP, Izpisua-Belmonte JC, et al. DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development. Proc Natl Acad Sci USA 1999; 96: 7992-7.
50. Garcia-Domingo D, Ramirez D, Gonzalez de Buitrago G, Martinez AC. Death inducer-obliterator 1 triggers apoptosis after nuclear translocation and caspase upregulation. Mol Cell Biol 2003; 23: 3216-25.
51. Futterer A, Campanero MR, Leonardo E, Criado LM, Flores JM, Hernandez JM, et al. Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J Clin Invest 2005; 115: 2351-62.
52. Wang Y, Chen Y, Chen Z, Wu Q, Ke WJ, Wu QL. Gambogic acid induces death inducer-obliterator 1-mediated apoptosis in Jurkat T cells. Acta Pharmacol Sin 2008; 29: 349-54.
53. Packham G. The role of NF-kappaB in lymphoid malignancies. Br J Haematol 2008; 143: 3-15.
54. Wang Y, Chen Y, Chen Z, Ke WJ, Wu QL, He J. Mechanism of gambogic acid-induced apoptosis in Raji cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009; 17: 88-91.
55. Lu L, Tang D, Wang L, Huang LQ, Jiang GS, Xiao XY, et al. Gambogic acid inhibits TNF-alpha-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-kappaB signaling pathways. Acta Pharmacol Sin 2012; 33: 531-41.
56. Wonderlin WF, Strobl JS. Potassium channels, proliferation and G1 progression. J Membr Biol 1996; 154: 91-107.
57. Pillozzi S, Brizzi MF, Balzi M, Crociani O, Cherubini A, Guasti L, et al. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 2002; 16: 1791-8.
58. Asher V, Sowter H, Shaw R, Bali A, Khan R. Eag and HERG potassium channels as novel therapeutic targets in cancer. World J Surg Oncol 2010; 8: 113.
59. Wang H, Zhang Y, Cao L, Han H, Wang J, Yang B, et al. HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. Cancer Res 2002; 62: 4843-8.
60. Smith GA, Tsui HW, Newell EW, Jiang X, Zhu XP, Tsui FW, et al. Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem 2002; 277: 18528-34.
61. Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, et al. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 2007; 110: 1238-50.
62. Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H, et al. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res 2004; 64: 606-11.
63. Zhao J, Wei XL, Jia YS, Zheng JQ. Silencing of herg gene by shRNA inhibits SH-SY5Y cell growth in vitro and in vivo. Eur J Pharmacol 2008; 579: 50-7.
64. Cui G, Shu W, Wu Q, Chen Y. Effect of Gambogic acid on the regulation of hERG channel in K562 cells in vitro. J Huazhong Univ Sci Technolog Med Sci 2009; 29: 540-5.
65. Scherz-Shouval R, Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci 2011; 36: 30-8.
66. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NFkappaB signaling. Cell Res 2011; 21: 103-15.
67. Liu B, Chen Y, St Clair DK. ROS and p53: a versatile partnership. Free Radic Biol Med 2008; 44: 1529-35.
68. Terada LS. Specificity in reactive oxidant signaling: think globally, act locally. J Cell Biol 2006; 174: 615-23.
69. Jones DP. Redefining oxidative stress. Antioxid Redox Signal 2006; 8: 1865-79.
70. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
71. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 2007; 7: 147-56.
72. Marnett LJ, Riggins JN, West JD. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Invest 2003; 111: 583-93.
73. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 2010; 48: 749-62.
74. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. J Cell Biol 1999; 144: 281-92.
75. Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, Drewe J, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA 2005; 102: 12095-100.
76. Chen YC, Shen SC, Tsai SH. Prostaglandin D2 and J2 induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochim Biophys Acta 2005; 1743: 291-304.
77. Kondo M, Shibata T, Kumagai T, Osawa T, Shibata N, Kobayashi M, et al. 15-Deoxy-Delta(12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci USA 2002; 99: 7367-72.
78. Zhou Z, Wang J. Phase I human tolerability trial of gambogic acid. Chin J New Drugs 2007; 16: 79-83.
79. Zhan X. The summary report of Phase IIa clinical trial of gambogic acid injection [dissertation]. Peking: Peking Union Medical College; 2008.